Such LHRH analogues have consistently resulted in a significant reduction in circulating testosterone along with tumor shrinkage and relief of symptoms.12 However, the vast majority of these patients eventually develop progression of disease (often manifesting as PSA elevations) within 12–36 months of ADT, indicating reactivated AR signaling and often necessitating other forms of treatment including chemotherapy. The gene discussed is KLK3; the disease is neoplasm.